Literature DB >> 25596808

Self-administered outpatient parenteral antimicrobial therapy (S-OPAT) for infective endocarditis: a safe and effective model.

Marcos Pajarón1, Manuel F Fernández-Miera2, Iciar Allende3, Ana M Arnaiz4, Manuel Gutiérrez-Cuadra5, Manuel Cobo-Belaustegui6, Carlos Armiñanzas7, Jose R de Berrazueta8, Maria C Fariñas9, Pedro Sanroma10.   

Abstract

The safety and efficacy of treatment of infectious endocarditis (IE) was evaluated within a program of hospital-in-home (HIH) based on self-administered outpatient parenteral antimicrobial therapy (S-OPAT). IE episodes (n=48 in 45 patients; 71% middle-aged males) were recruited into the HIH program between 1998 and 2012. Following treatment stabilization at the hospital they returned home for HIH in which a physician and/or a nurse supervised the S-OPAT. Safety and efficacy were evaluated as mortality, re-occurrence, and unexpected re-admission to hospital. Of the episodes of IE, 83.3% had comorbidities with a mean score of 2.3 on the Charlson index and 1.5 on the Profund index; 60.4% had pre-existing valve disease (58.6% having had surgical intervention); 8.3% of patients had suffered a previous IE episode; 62.5% of all episodes affected a native valve; 45.8% being mitral; 70.8% of infection derived from the community. In 75% of the episodes there was micro-organism growth, of which 83.3% were Gram positive. Overall duration of antibiotic treatment was 4.8 weeks; 60.4% of this time corresponding to HIH. Re-admission occurred in 12.5% of episodes of which 33.3% returned to HIH to complete the S-OPAT. No deaths occurred during HIH. One year after discharge, 2 patients had recurrence and 5 patients died, in 2 of whom previous IE as cause-of-death could not be excluded. In conclusion, the S-OPAT schedule of hospital-in-home is safe and efficacious in selected patients with IE.
Copyright © 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complications; H-OPAT; Home intravenous therapy; Hospital-in-home; S-OPAT; Self-administration

Mesh:

Substances:

Year:  2015        PMID: 25596808     DOI: 10.1016/j.ejim.2015.01.001

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

Review 1.  Treatment of infections caused by multi-resistant microorganisms in hospital at home units.

Authors:  M Mirón-Rubio
Journal:  Rev Esp Quimioter       Date:  2021-09-30       Impact factor: 1.553

2.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

Review 3.  Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

Authors:  E D Mitchell; C Czoski Murray; D Meads; J Minton; J Wright; M Twiddy
Journal:  BMJ Open       Date:  2017-04-20       Impact factor: 2.692

4.  Implementing the First Outpatient Parenteral Antimicrobial Therapy (OPAT) Program to Utilize Disposable Elastomeric Pumps in the Gulf Region: Results From a Tertiary Teaching Hospital in the Kingdom of Saudi Arabia.

Authors:  Ahmed Zikri; Hassan Al-Faraj; Nabil Kamas; Jumaan AlZahrani; Hisham BuKhamseen; Wasan Alshahoub; Arlene Beltran; Dalia Fatih; Zainab AlMusa
Journal:  Cureus       Date:  2021-12-05

5.  Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis.

Authors:  W Wen; H Li; C Wang; C Chen; J Tang; M Zhou; X Hong; Y Cheng; Q Wu; X Zhang; Z Feng; M Wang
Journal:  Rev Esp Quimioter       Date:  2022-06-02       Impact factor: 2.515

6.  Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria.

Authors:  Juan M Pericàs; Jaume Llopis; Patricia Muñoz; Víctor González-Ramallo; M Eugenia García-Leoni; Arístides de Alarcón; Rafael Luque; M Carmen Fariñas; Miguel Á Goenaga; Marta Hernández-Meneses; David Nicolás; Antonio Ramos-Martínez; M Ángeles Rodríguez-Esteban; Aroa Villoslada-Gelabert; José M Miró
Journal:  Open Forum Infect Dis       Date:  2022-08-30       Impact factor: 4.423

7.  Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial.

Authors:  Danielle B Cohen; Kuzani Mbendera; Hendramoorthy Maheswaran; Mavuto Mukaka; Helen Mangochi; Linna Phiri; Jason Madan; Geraint Davies; Elizabeth Corbett; Bertel Squire
Journal:  Thorax       Date:  2019-11-01       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.